Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
about
Approaches to modernize the combination drug development paradigmCase Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agentsVenous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.Phase 1 trial design: is 3 + 3 the best?The changing landscape of phase I trials in oncology.An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials.Determinants of the recommended phase 2 dose of molecular targeted agents.Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study.Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications.Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.Patient-reported tolerability of adverse events in phase 1 trials.
P2860
Q28072074-EE6CBDC6-2DD3-4829-8BE7-C5A080B88BFEQ31050273-D5632A7F-8336-4116-80E5-F101431EF179Q33422932-219DB433-BD89-4EE5-A96F-EC51ED933F13Q33431175-EF307841-ACE4-47B1-B046-770815EB9A0CQ33822083-3ADA41FE-0A09-41FB-8A75-D5AE8D595728Q34516049-EDE549F4-6F1E-4C67-9D7A-6BFA7CC1DEE7Q35835156-7A403F92-A12C-4D84-B4ED-F74F245FAF2BQ36166850-2AA4CABC-0DDB-4903-BF7B-E22534319A22Q36326389-8C51F331-4B21-49DE-84F5-C0B7E914F94AQ37063738-F79F1A9B-DF4F-4DBB-9B53-1A588FD4E6F5Q38222466-83F81571-9595-4D7A-A56D-A1A98DB476E2Q38629203-ED165BBE-A10C-4A52-9416-5AD2FAFECFE1Q38735192-E0C67B95-757A-4A2C-B2FA-1C17865BA914Q39128248-4AA59987-7ECF-43C3-9019-2768461EC6DAQ39166183-35296476-D9C8-4635-99BF-597C507F8ABCQ47108689-E1D18171-50E7-4004-8E44-74620E282F7DQ47223679-C6073F4C-1746-4F31-8F0A-8CF5BDFDAD57Q47987968-359A5C67-33A6-4557-B30D-6E80FEC20C69Q48254839-64510195-BE0C-4017-B8C1-6911C0853C7FQ53522981-1AB09994-35D5-4B31-9973-68C0DA5A4781Q55287059-51A69BE5-BDA9-4D9C-8FA8-7087F22976C5
P2860
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heterogeneity in the definitio ...... s: a review of the literature.
@en
Heterogeneity in the definitio ...... s: a review of the literature.
@nl
type
label
Heterogeneity in the definitio ...... s: a review of the literature.
@en
Heterogeneity in the definitio ...... s: a review of the literature.
@nl
prefLabel
Heterogeneity in the definitio ...... s: a review of the literature.
@en
Heterogeneity in the definitio ...... s: a review of the literature.
@nl
P2093
P1476
Heterogeneity in the definitio ...... s: a review of the literature.
@en
P2093
Albiruni R A Razak
Patricia Tresca
Simona Pop
Véronique Diéras
Xavier Paoletti
P304
P356
10.1016/J.EJCA.2011.03.016
P577
2011-04-07T00:00:00Z